Welcome to our dedicated page for Whitehawk Therapeutics SEC filings (Ticker: WHWK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics, Inc. reported a net loss of $16.6 million for the quarter and $38.8 million for the six months ended June 30, 2026, with no product revenue following the March 2025 divestiture of its FYARRO business. Operating expenses for the first half totaled $41.6 million, driven mainly by $30.1 million in research and development and $11.5 million in selling, general and administrative costs.
Other income for the first half of 2026 was $2.8 million, primarily interest on the company’s investment portfolio. After the FYARRO sale, Whitehawk is focused on a portfolio of three next-generation antibody drug conjugates licensed from WuXi Biologics, with two clinical and one preclinical-stage candidates.
Liquidity is strong: at June 30, 2026, cash, cash equivalents and short-term investments were $190.0 million, total liabilities were $11.1 million, and stockholders’ equity was $182.9 million. Net cash used in operating activities was $36.7 million for the first half, largely offset by $81.8 million in net proceeds from a May 2026 PIPE financing. Management states existing funds are expected to support operations into the second half of 2028.
Whitehawk Therapeutics, a clinical-stage oncology company focused on antibody drug conjugates, reported second quarter 2026 results. Cash, cash equivalents and short-term investments were $190.0 million as of June 30, 2026, up from $145.7 million at December 31, 2025, and are expected to fund operations into 2H 2028.
The company continued enrolling patients in Phase 1 trials of HWK-007 and HWK-016 and plans to initiate a Phase 1 study of HWK-206 in small-cell lung cancer and neuroendocrine tumors in Q3 2026, with initial Phase 1 data for HWK-007 and HWK-016 anticipated in 1H 2027. Whitehawk expanded its platform through an option agreement with Hangzhou DAC for CPT113-based ADCs and a global collaboration with Biocytogen to access up to five bispecific antibodies using the RenLite platform.
Research and development expenses were $12.9 million for the quarter, compared with $48.8 million a year earlier, when results included a $38.0 million up-front license fee to WuXi Biologics. Net loss was $16.6 million, or $0.20 per share, versus a net loss of $52.6 million, or $0.76 per share, in the prior-year quarter.
Whitehawk Therapeutics, Inc. director Anupam Dalal reported two equity-related acquisitions. He was granted 38,040 stock options with an exercise price of $4.16 per share, expiring in 2036; all options vest on the earlier of one year from the June 12, 2026 grant date or immediately before the next annual stockholders’ meeting, subject to continued service.
Dalal also reported an indirect acquisition of 1,275,510 shares of common stock at $3.92 per share, held through Acuta Capital Fund, LP and Acuta Opportunity Fund, LP, bringing his reported indirect holdings via these funds to 4,685,912 shares. He has voting and investment authority over these fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest. Separately, he holds 1,130 common shares directly.
Whitehawk Therapeutics director Baiteng Zhao received a grant of stock options as compensation. On the grant date, Zhao was awarded options for 38,040 shares of common stock at an exercise price of $4.16 per share, expiring on June 12, 2036. All options vest 100% after about one year or just before the next annual stockholder meeting, as long as Zhao continues serving the company.
Whitehawk Therapeutics director Emma Reeve received a stock option grant, giving her the right to buy 38,040 shares of common stock at an exercise price of $4.16 per share. The option was granted as a compensation award with no cash paid at grant.
The option expires on June 12, 2036. All 38,040 shares subject to the option vest 100% on the earlier of one year after the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting, as long as she continues as a service provider. Following this grant, she holds options covering 38,040 shares directly.
Whitehawk Therapeutics director Richard E. Maroun received a grant of stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036. All 38,040 option shares will vest in a single tranche, subject to his continued service, on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting following that date. After this award, he holds 38,040 derivative securities directly.
Whitehawk Therapeutics director Mohammad Hirmand received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036.
All 38,040 option shares will vest 100% on the earlier of the one-year anniversary of the grant date or the day immediately before the next annual stockholder meeting, as long as he continues as a service provider. Following this grant, he holds 38,040 stock options directly from this award.
Whitehawk Therapeutics director Neil Desai received a new stock option grant. The Form 4 shows an award of options covering 38,040 shares of common stock at an exercise price of $4.1600 per share, expiring on June 12, 2036.
All 38,040 option shares vest in a single tranche, subject to Mr. Desai continuing as a service provider. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics director Caley Castelein received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036. Following this grant, Castelein holds stock options for 38,040 underlying shares directly.
According to the award terms, all 38,040 option shares vest 100% if Castelein continues as a service provider until the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately prior to the next annual stockholder meeting after that grant date.
Whitehawk Therapeutics, Inc. reported that director and 10% owner Behzad Aghazadeh was granted stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036.
According to the terms, all 38,040 underlying shares vest in a single tranche if the reporting person continues to be a service provider through the earlier of the one-year anniversary of the grant date or the day immediately before the next annual shareholder meeting, with a grant date of June 12, 2026. The filing is made jointly by Avoro Capital Advisors LLC, Avoro Ventures LLC, and Dr. Aghazadeh, who each disclaim beneficial ownership beyond their pecuniary interest.